Mobile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011800-44

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Co-Primary Objectives: • To determine the effect of Dimebon as compared to placebo on cognition as measured by the Mini-Mental State Examination (MMSE); and • To determine the effect of Dimebon as compared to placebo on the primary measure of global function, the Clinician’s Interview-Based Impression of Change, plus caregiver input (CIBIC-plus).

Critère d'inclusion

  • Huntington disease

Liens